Cardiovascular magnetic resonance in muscular dystrophies: looking ahead

Data de publicação:

Unidades de investigação

Abstract

<jats:p>Cardiac magnetic resonance (CMR) is an established tool for risk stratification in several cardiomyopathies, and its role in muscular dystrophies (MuD) looks promising. We sought to assess how CMR performs in predicting cardiac events in a real cohort of MuD patients. A prospective single-center study with the enrollment of consecutive adult MuD patients referred to cardiac screening from 2012 to 2018 with the collection of clinical and CMR data. During follow-up (FUP), major adverse cardiac events were considered a composite of device implantation, ventricular tachycardia (VT), hospitalization due to heart failure, and death. Sixty-five patients were included (mean age of 32?16, 51% female); the majority had myotonic dystrophy (34; 52.3%); most were asymptomatic (60; 92.3%) and at sinus rhythm (64; 98.5%). CMR was abnormal in 23 (43.3%) patients: left ventricle ejection fraction (LVEF) lt;55% was found in 7 patients, and late gadolinium enhancement (LGE) was present in 23 patients, mainly intra-myocardial or subepicardial (10 and 8 patients, respectively). During a median FUP of 77 months (interquartile range: 33), there were 7 deaths, 8 implanted devices, and one sustained VT. LVEFlt;55% and the presence of LGE were associated with the occurrence of all events (log rank test, p=0.002 and p=0.045, respectively). LVEFlt;55% was associated with a 6-fold higher risk of events (crude hazard ratio of 6.15; 95% confidence interval of 1.65-22.93), that remained significant after adjusting for LGE presence (adjusted hazard ratio of 4.81, 95% confidence interval of 1.07-15.9). In our cohort, CMR LVEFlt;55% and the presence of LGE were significantly associated with adverse events during follow-up, reinforcing the role of this technique on risk stratification of MuD populations.</jats:p>

Dados da publicação

ISSN/ISSNe:
1122-0643, 2532-5264

Monaldi Archives for Chest Disease  PagePress Publications

Tipo:
Article
Páginas:
-

Documentos

  • Não há documentos

Métricas

Filiações

Filiações não disponíveis

Proyectos asociados

Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION) - NCT05465213

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo Observacional Comercial (EVOLUTION) . AstraZeneca . 2023

Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies (F-CHECK) - NCT05409846

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico (F-CHECK) . Sanofi . 2022

Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population (CarPoS) - NCT05409833

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico (CarPoS) . Pfizer . 2020

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS) - NCT05021835

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Ensaio Clínico Comercial (ZEUS) . Novo Nordisk . 2022

Rastreio da Doença de Fabry em doentes com cardiomiopatias de etiologia desconhecida.

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico( FABRY) . 2022

Serositis in patients with Systemic Lupus Erythematosus: characteristics and associates

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico (Serositis) . 2023

PR Interval in Hypertrophic Cardiomyopathy patients: an easy and worthy risk factor?

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico (Cardiomyopathy) . 2023

High-sensitivity cardiac troponin I as a reliable prognosis biomarker in patients with hypertrophic cardiomyopathy

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico (Troponin I) . 2023

Transthyretin Cardiac Amyloidosis - novel and emerging treatments

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2021

Avaliação do risco de Morte Súbita Cardíaca em doentes com miocardiopatia hipertrófica - Comparação das directrizes Europeias e Americanas

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2022

Insuficiência Cardíaca na Miocardiopatia Hipertrófica: Preditores, Manifestações Clínicas e Tratamento

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2023

Estudo das alterações cardíacas ictais: possível relação com a morte súbita na epilepsia.

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2023

Miocardiopatia dilatada genética - contributo das novas técnicas de diagnóstico molecular e de imagem

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação